A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS
A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS
M. Bozik,H. Mitsumoto,9 Authors,D. Archibald
2014 · DOI: 10.3109/21678421.2014.943672
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · 48 Citations